NC-LENOVO
25.2.2021 15:02:09 CET | Business Wire | Press release
The world’s greatest adventure and action sports imagery contest, Red Bull Illume® returns in 2021 with global technology leader, Lenovo™, as its Exclusive Computing Sponsor. A showcase for the best of adventure and action sports imagery, the competition is expected once again to receive tens of thousands of entries from around the world including some of the most creative and extreme images ever captured. As part of this two-year partnership, Lenovo will be involved through brand, product placement and logo incorporation for both online and in-person content, prizes for finalists and winners, as well as having promotional access to the incredible contest imagery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005071/en/
Lenovo enables a more inclusive and inspired world for all through smarter technology, so it’s fitting Lenovo should present this year’s Best of Instagram category that opens up the competition to all. Unlike the contest’s nine other categories which are adjudicated by a panel of 50 photo and digital experts from around the world, the finalists and category winners for Best of Instagram by Lenovo are selected through public voting. Each month, from March 1 to July 31, 2021, there will be five still and five moving images pre-selected by an internal jury which are put out to a community vote. The top choices from each month will become official Red Bull Illume Image Quest 2021 Finalists; from these, a final online vote will decide the best still image and the best moving image, to be crowned as Lenovo’s Best of Instagram Category Winners. Anyone can submit their moving or still images on Instagram by tagging @redbullillume and #rbi21submission .
The Overall Winner of Red Bull Illume Image Quest 2021 is selected from all the category winners by the international judging panel. There is a total of 10 categories which are created to truly shine a light on the lifestyle and culture behind today’s professional and amateur content creators and their dedication to the craft. Each edition of the contest brings out a new level of never-seen-before creativity, and this edition is bound to be full of imagery that pushes the boundaries of content creation in adventure and action sports imagery.
Along with receiving well-earned career exposure as an official Red Bull Illume winner, their work will tour the globe, illuminated on huge lightboxes. The winners are also awarded prize packages that include trophies and the latest Lenovo products to power even more creative self-expression. Their work will be included in the official Red Bull Illume photobook and showcased during the winner award ceremony planned for November 2021 and attended by Ulrich Grill, the founder of the Red Bull Illume Image Quest.
“Lenovo is proud to support the sixth edition of Red Bull Illume Image Quest that brings together photographers and content creators whose bold work continually inspires us,” said Matt Bereda, Vice President of Global Consumer Marketing, PCs and Smart Devices, Lenovo . “We see many of our consumer PC, smart home, and tablet customers are passionate hobbyists. They enjoy photography and digital storytelling, and not all of them are paid professionals—they just love capturing and enhancing imagery to share with others and hang on their walls. If this new normal has taught us anything about our world and ourselves, it’s that we’re resilient, our technology is adaptable, and that making meaningful connections with others through shared creative pursuits are the bright spots in life that really matter.”
“Red Bull Illume is like the Oscars of adventure and action sports imagery and we are extremely proud to have Lenovo join the 2021 edition,” said Ulrich Grill, Founder of Red Bull Illume . “This contest honors the creativity and hard work that goes into producing one-of-a-kind imagery and Lenovo gives content creators the tools they need to express their unique ideas.”
A shared dedication to transformative experiences and using innovative technology to push boundaries makes Red Bull Illume and Lenovo ideal partners. Meaningful innovation is essential to advancing photo technologies and solidifying image capture as an artform. Similarly, Lenovo innovation provides digital creators with better photo management and enhancement experiences and smarter technology so they can build bigger for a more creative world – making consumer products, services, and software solutions more attuned to the unique needs of modern content creators.
The contest is open for submissions from March 1 to July 31, 2021. It is free for anyone to enter and voting is open to all on redbullillume.com . To view previous winning images, check out the gallery, here .
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$50 billion Fortune Global 500 company, with 63,000 employees and operating in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that create a more inclusive, trustworthy and sustainable digital society. By designing, engineering and building the world’s most complete portfolio of smart devices and infrastructure, we are also leading an Intelligent Transformation – to create better experiences and opportunities for millions of customers around the world. To find out more visit https://www.lenovo.com , follow us on LinkedIn , Facebook , Twitter , YouTube , Instagram , Weibo and read about the latest news via our StoryHub .
About Red Bull Illume
The Image Quest 2021 is the sixth edition bringing together the amazing work of photographers and content creators from around the world. In 2019, a record-breaking 59,551 images were submitted by thousands of creators from countries all around the world. Submissions for the contest will take place from March 1 to July 31, 2021 and can be entered on redbullillume.com and on Instagram. A judging panel of 50 photo editors and digital experts will select the Finalists, Category Winners and an Overall Winner, to be unveiled at the Winner Award Ceremony in November 2021. Follow us on Instagram, Facebook, Twitter, YouTube and Pinterest.
LENOVO is a trademark of Lenovo. RED BULL ILLUME is a trademark of Red Bull GmbH. Instagram is a trademark of Instagram, LLC. All other trademarks are the property of their respective owners. ©2021, Lenovo Group Limited.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005071/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom